DLD抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06323(GHRH Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

DLD (dihydrolipoamide dehydrogenase) antibodies target a mitochondrial enzyme critical in energy metabolism. DLD, also known as E3 component, is a flavoprotein essential for multiple dehydrogenase complexes, including the pyruvate dehydrogenase complex (PDC), α-ketoglutarate dehydrogenase, and branched-chain α-keto acid dehydrogenase. It catalyzes the oxidation of dihydrolipoamide to lipoamide, facilitating NADH production in the tricarboxylic acid (TCA) cycle.

DLD deficiency, a rare autosomal recessive disorder, causes metabolic disturbances such as lactic acidosis, neurological impairment, and liver dysfunction. Autoantibodies against DLD are occasionally detected in autoimmune conditions. For instance, anti-PDC antibodies in primary biliary cholangitis (PBC) often cross-react with DLD due to shared epitopes within the dehydrogenase complexes.

In research, DLD antibodies are widely used to study mitochondrial dysfunction, metabolic diseases, and cancer metabolism. Elevated DLD expression has been linked to tumor progression, as cancer cells rely on altered TCA cycle activity for proliferation. Commercially available antibodies enable detection of DLD in tissues or cells via techniques like Western blotting and immunohistochemistry.

Overall, DLD antibodies serve dual roles: as diagnostic tools in metabolic disorders and autoimmune diseases, and as research reagents to explore cellular energy regulation and disease mechanisms. Their significance spans clinical diagnostics, therapeutic target identification, and basic mitochondrial biology.